MYST4 Blocking Peptide
- Known as:
- MYST4 Blocking Peptide
- Catalog number:
- 33r-6590
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- MYST4 Blocking Peptide
Related genes to: MYST4 Blocking Peptide
- Gene:
- KAT6B NIH gene
- Name:
- lysine acetyltransferase 6B
- Previous symbol:
- MYST4
- Synonyms:
- querkopf, qkf, Morf, MOZ2, ZC2HC6B
- Chromosome:
- 10q22.2
- Locus Type:
- gene with protein product
- Date approved:
- 2003-06-03
- Date modifiied:
- 2016-02-12
Related products to: MYST4 Blocking Peptide
Related articles to: MYST4 Blocking Peptide
- Several studies have demonstrated the value of large-scale human exome and genome data analysis to maximise gene discovery in rare diseases. Using this approach, we have analysed the exomes of 4747 cases and 52,881 controls to identify genes which confer a substantial risk of congenital heart disease (CHD). We identified both rare loss-of-function and missense coding variants in 14 genes, which reached genome-wide significance at FDR 5%. Ten genes have been associated with CHD, whereas four genes (PBX1, KAT6B, SHOX2, HCAR1) have not been reported as genome-wide significant so far. We highlight distinct genetic contributions to syndromic and non-syndromic CHD by independently analysing probands from these two groups. In addition, by integrative analysis of exome data with single-cell transcriptomics data from human embryonic hearts, we identified cardiac-specific cells, such as neural crest cells and endothelial cells, as well as putative biological processes underlying the pathogenesis of CHD. In summary, our findings strengthen the association of known CHD genes and have identified additional novel disease genes contributing to the aetiology of CHD. - Source: PubMed
Publication date: 2026/06/02
Audain EnriqueWilsdon AnnaDombrowsky GregorSifrim AlejandroBreckpot JeroenPerez-Riverol YassetLoughna SiobhanDaly AllanAntoniou PavlosHofmann PhilippPerez-Riverol AmilcarKahlert Anne-KarinBauer UlrikePickardt ThomasKlaassen SabineBerger FelixDaehnert IngoDittrich SvenStiller BrigitteAbdul-Khaliq HashimBu'lock FrancesUebing AnselmKramer Hans-HeinerIyer VivekLarsen Lars AllanBrook J DavidHitz Marc-Phillip - KAT6A (MOZ) and KAT6B (QKF/MORF) are related histone lysine acetyltransferases (KATs) that have a high degree of functional redundancy during development. In the absence of KAT6A embryos undergo an anterior homeotic transformation of the axial skeleton, develop an interrupted aortic arch, have ventricular septal defects and fail to form definitive hematopoietic stem cells. KAT6B has roles in brain, skeletal and hematopoietic system development. Since loss of KAT6A leads to highly penetrant phenotypes this allows us to determine if the acetylation function is essential for all activities. We show that loss of acetyltransferase activity did not phenocopy the loss of the KAT6A protein. While the mutation the KAT domains of both KAT6A and KAT6B together increased the severity of phenotypes observed, these were milder than complete KAT6A loss of function. KAT domain mutants displayed ventricular septal defects and reduced (but not eliminated) hematopoietic stem cell activity. However, they did not display homeotic transformations or aortic arch defects, suggesting that while acetylation is important some functions, others can proceed without this activity. Accordingly, KAT6 proteins appear to have functions beyond acetylation. - Source: PubMed
Publication date: 2026/06/02
Thomas TimMalelang ShezlieYang YuqingBergamasco Maria IKueh Andrew JGarnham Alexandra LRanathunga NishikaSmyth Gordon KVoss Anne K - Metabolic dysfunction-associated steatohepatitis (MASH) is a severe clinical complication of metabolic syndrome, but effective pharmacological treatments remain scarce. This study investigated the role of lactylation-a novel post-translational modification-in the pathogenesis of MASH, using murine models. - Source: PubMed
Publication date: 2026/06/01
Sun YiWang ChangyuanWang YangHao RuLiu LuCao MinSun Huijun - Not available. - Source: PubMed
Publication date: 2026/04/23
Voss Rebecca KQi WenqingBrowne La'RonWang'ondu Ruth WKhanlari MahsaMa JingMa XuefeiLott JosiBarajas Juan MThomas Iii MelvinLoyola Victor B PastorCao HuiFurtado Larissa VNaik SwatiBami SakshiKarol Seth ERubnitz Jeffrey EKlco Jeffery MLiu Yen-ChunWang Lu - KAT6A and its paralog KAT6B (KAT6) are part of the MYST family of histone acetyltransferases. KAT6 is involved in regulating multiple cellular processes by acetylating different lysine residues on histone H3. While KAT6A is overexpressed in various solid tumors, KAT6 is best characterized for its role in transcription in estrogen receptor-positive (ER+) breast cancer. - Source: PubMed
Publication date: 2026/02/22
Mukohara Toru